A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Completed

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.

Key facts

Study ID

NCT01339481

Run by

Astellas Pharma Inc

People needed

26

Starts

2011-02-01

Expected to finish

2011-10-01

Last updated by the study team

2011-11-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has rheumatoid arthritis (RA), is both abatacept- and belatacept-naïve, and is an eligible candidate to start a course of treatment with abatacept in accordance with the product label
• Subject is willing and able to comply with study visits and procedures

Where it is running

• Pinnacle Research Group, LLC — Anniston, Alabama, United States
• Arthritis Research of Florida — Palm Harbor, Florida, United States
• The Center for Rheumatology and Bone Research — Wheaton, Maryland, United States
• North Shore - Long Island Jewish Health System — Lake Success, New York, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
• Low County Rheumatology — North Charleston, South Carolina, United States
• Metroplex Clinical Research Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.